Correction: Changes in innate and permissive immune responses after HBV transgenic mouse vaccination and long-term-siRNA treatment (PLoS ONE) 8, 3 (e57525) DOI: 10.1371/journal.pone.0057525;Changes in Innate and Permissive Immune Responses after HBV Transgenic Mouse Vaccination and lLong-Term-siRNA Treatment

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Ren, Guang Li ^a,b   Huang, Guang Yu ^c   Zheng, Hong ^d   Fang, Ying ^e   Ma, Heng Hao ^a   Xu, Man Chun ^a   Zhang, Hong Bin ^a   Zhang, Wei Yun ^a   Zhao, Ya Gang ^a   Sun, Da Yong ^a   Hu, Wen Kui ^a   Liu, Jian ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA INTERFERON; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 6; ODN 1826; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; OLIGONUCLEOTIDE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSE COMPARISON; GENE EXPRESSION; GENE REPLICATION; HEPATITIS B; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LIVER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; TRANSGENIC MOUSE; VIRAL CLEARANCE; ANIMAL; BAGG ALBINO MOUSE; CPG ISLAND; GENE SILENCING; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; PATHOLOGY; VACCINATION;

ADAPTIVE IMMUNITY; ANIMALS; CPG ISLANDS; CYTOKINES; GENE SILENCING; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; IMMUNITY, INNATE; LIVER; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OLIGONUCLEOTIDES; RNA, SMALL INTERFERING; VACCINATION;

EID: 84874622721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/annotation/d0e70062-ac3b-47a6-ab1e-402ed08affa4     Document Type: Erratum

References (31)

1. Lai CL, Yuen MF, (2008) Chronic hepatitis B-new goals, new treatment. N Engl J Med 359: 2488-2491.
2. Liaw YF, Chu CM, (2009) Hepatitis B virus infection. Lancet 373: 582-592.
3. Plasterk RH, (2002) RNA silencing: the genome's immune system. Science 296: 1263-1265.
4. Ren GL, Bai XF, Zhang Y, Chen HM, Huang CX, et al. (2005) Stable inhibition of hepatitis B virus expression and replication by expressed siRNA. Biochem Biophys Res Commun 335: 1051-1059.
5. Ren GL, Fang Y, Ma HH, Lei YF, Wang D, et al. (2007) The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains. Antivir Ther 12: 865-876.
6. Wen WH, Liu JY, Qin WJ, Zhao J, Wang T, et al. (2007) Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 46: 84-94.
7. Chen CC, Sun CP, Ma HI, Fang CC, Wu PY, et al. (2009) Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther 17: 352-359.
8. Giering JC, Grimm D, Storm TA, Kay MA, (2008) Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16: 1630-1636.
9. Hannon GJ, (2002) RNA interference. Nature 418: 244-251.
10. Raimondo G, Pollicino T, Cacciola I, Squadrito G, (2007) Occult hepatitis B virus infection. J Hepatol 46: 160-170.
11. Starkey JL, Chiari EF, Isom HC, (2009) Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. J Gen Virol 90: 115-126.
12. Wu J, Meng Z, Jiang M, Pei R, Trippler M, et al. (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49: 1132-1140.
13. Durantel D, Zoulim F, (2012) Interplay between hepatitis B virus and TLR2-mediated innate immune responses: Can restoration of TLR2 functions be a new therapeutic option? J Hepatol 57: 486-489.
14. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, et al. (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137: 1289-1300.
15. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, et al. (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58: 974-982.
16. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98: 9237-9242.
17. Uprichard SL, Boyd B, Althage A, Chisari FV, (2005) Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A 102: 773-778.
18. Kakazu E, Ueno Y, Kondo Y, Fukushima K, Shiina M, et al. (2009) Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology 50: 1936-1945.
19. Zhang JC, Sun L, Nie QH, Huang CX, Jia ZS, et al. (2009) Down-regulation of CXCR4 expression by SDF-KDEL in CD34(+) hematopoietic stem cells: An anti-human immunodeficiency virus strategy. J Virol Methods 161: 30-37.
20. Nassanian H, Sanchez AM, Lo A, Bradley KA, Lee B, (2007) Efficient construction of an inverted minimal H1 promoter driven siRNA expression cassette: facilitation of promoter and siRNA sequence exchange. PLoS One 2: e767.
21. Xu Z, Huang CX, Li Y, Wang PZ, Ren GL, et al. (2007) Toll-like receptor 4 siRNA attenuates LPS-induced secretion of inflammatory cytokines and chemokines by macrophages. J Infect 55: e1-9.
22. Sibley CR, Seow Y, Wood MJ, (2010) Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 18: 466-476.
23. Carmona S, Jorgensen MR, Kolli S, Crowther C, Salazar FH, et al. (2009) Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm 6: 706-717.
24. Lee Y, Kim M, Han J, Yeom KH, Lee S, et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-4060.
25. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637.
26. Beutler B, (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
27. Wu J, Lu M, Meng Z, Trippler M, Broering R, et al. (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46: 1769-1778.
28. Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, et al. (2005) Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology 128: 2042-2053.
29. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, et al. (2002) Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196: 1091-1097.
30. Young LJ, Wilson NS, Schnorrer P, Proietto A, ten Broeke T, et al. (2008) Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol 9: 1244-1252.
31. Xiao C, Rajewsky K, (2009) MicroRNA control in the immune system: basic principles. Cell 136: 26-36.